Vertex’s Cystic Fibrosis Sales Beat, as Newer Drugs Miss

Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay ...

Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% ...
The Motley Fool

Is It Too Late to Buy Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals is a rare-disease drugmaker with over $10 billion in annual sales. The company's lead drug is the only available treatment for cystic fibrosis, a life-threatening progressive ...
Zacks.com on MSN

Vertex Pharmaceuticals (VRTX) Stock Moves -1.23%: What You Should Know

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $417.21, denoting a -1.23% move from the preceding trading day.
Nasdaq

If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the fastest-growing healthcare companies in recent years. Its products have made it a leader in cystic fibrosis (CF) treatment and it has been ...

Vertex’s cystic fibrosis sales beat expectations, as newer drugs miss

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...
The Motley Fool

If You Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, This Is How Much You Would Have Today

Vertex has proved itself as a solid long-term investment. The company has reached an important turning point -- that could mean more blockbuster revenue down the road. The past few years have brought ...